Revenue
No reported data
Semnur Pharmaceuticals, Inc. (SMNR)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $2.5M | $1.7M | — | — |
| Operating expenses | $160.4M | $4.7M | $3.2M | $1.6M |
| Operating income | −$160.4M | −$4.7M | −$3.2M | — |
| Net income | −$160.4M | −$4.7M | $632,536 | −$419,390 |
| Basic EPSper diluted share | -$0.78 | -$0.02 | — | — |
| Diluted EPSper diluted share | -$0.78 | -$0.02 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 23, 2025Form 4 | Scilex Holding Co +1TenPercentOwner | SellCommon Stock | 554.8K | $16.00 | $8.88M | 500.0K |
| Sep 23, 2025Form 4 | Scilex Holding Co +1TenPercentOwner | SellCommon Stock · indirect | 11.95M | $16.00 | $191.12M | 181.80M |
| Aug 30, 2024Form 4 | Denali Capital Global Investments LLCTenPercentOwner | SellClass B Ordinary Shares · derivative | 500.0K | — | — | 1.43M |
| Aug 30, 2024Form 4 | Xu JiandongTenPercentOwner | SellClass B Ordinary Shares · derivative · indirect | 500.0K | — | — | 1.43M |